Clinical trial · Interventional
RF Ablation of Treatment of Metastatic Lesions in Patients Undergoing Antiangiogenic Therapy for Stage IV Renal Cell Carcinoma
Pilot Feasibility Protocol of RF Ablation of Treatment of Metastatic Lesions in Patients Undergoing Antiangiogenic Therapy for Stage IV Renal Cell Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): This protocol was never officially opened and no patients were recruited.
Summary
Brief summary (as posted)
The purpose of this study is to look at the effects of a procedure called radiofrequency ablation on kidney tumors from patients who are undergoing antiangiogenic treatment. Antiangiogenic treatment is a type of treatment that inhibits formation of new blood vessels that are required for tumor growth. Radiofrequency ablation (RF ablation) involves inserting a needle into tumor tissue and administering heat to the tumor tissue that is sufficient to kill the tumor cells.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiofrequency Ablation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To evaluate the safety, toxicity and feasibility of RFA for the treatment of metastatic lesion in patients undergoing antiangiogenic therapy.
- timeFrame
- 3 years
Secondary outcomes (4)
- measure
- To evaluate the efficacy of RF ablation by measurement of diameter of ablation for treatment in this patient population.
- timeFrame
- 3 years
- measure
- To evaluate relative efficacy of RFA in treatment of metastatic lesions showing sensitivity vs. resistance to anti-angiogenic therapy.
- timeFrame
- 3 years
- measure
- To examine the mechanism of resistance to antiangiogenic therapy by examining the pathologic findings in sensitive and resistant metastatic lesions in patients with RCC treated with sorafenib and sunitinib.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who are on antiangiogenic therapy for a minimum of 4 weeks and have isolated metastatic lesions showing either persistence or resistance to therapy that might benefit from local therapy such as RF ablation. * Male or female patients 18 years of age or older * Clinical, radiographic, or pathologic diagnosis of clear cell RCC * Ongoing treatment with sorafenib or sunitinib, off clinical trials * Acceptable risk for general anesthesia in the judgement of the study investigator and by the department of anesthesiology upon preoperative testing. * At least one lesion that has not completely resolved while on antiangiogenic therapy * Candidate lesions of 1cm or greater in diameter * Safe access to the tumor for a needle placed under ultrasound guidance * ECOG Performance Status of 0 or 1 * Adequate bone marrow, and renal as assessed by the laboratory requirements outlined in the protocol Exclusion Criteria: * History of bleeding diathesis or unexpected surgical bleeding * Patients currently on anticoagulation * Medical contraindication to MR imaging (pacemaker, metal debris in eye, etc.) * Prior RF to the index tumor * Pregnant or lactating
References
Publications (0)
Data not yet available